ADAPTIVE BIOTECHNOLOGIES CORPORATION Payments to Acquire Marketable Securities
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Payments to Acquire Marketable Securities of $121.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for the quarter ending 2026-06-30 was $82.72M, a 61.77% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for the quarter ending 2026-03-31 was $38.86M, a 23.28% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for the quarter ending 2025-12-31 was $46.73M, a 4.31% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for the quarter ending 2025-09-30 was $33.19M, a 47.53% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for fiscal 2025 was $181.71M, a 25.61% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for fiscal 2024 was $244.26M, a 43.14% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for fiscal 2023 was $429.56M, a 54.09% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION payments to acquire marketable securities for fiscal 2022 was $278.78M, a 11.93% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $82.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $121.59M 10-Q · filed 2026-08-04 | $168.32M derived: sum of 3 quarters · filed 2026-08-04 | $201.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $38.86M 10-Q · filed 2026-05-05 | $85.59M derived: sum of 2 quarters · filed 2026-05-05 | $118.78M derived: sum of 3 quarters · filed 2026-05-05 | $169.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $46.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $79.92M derived: sum of 2 quarters · filed 2026-02-26 | $131.06M derived: sum of 3 quarters · filed 2026-08-04 | $181.71M 10-K · filed 2026-02-26 |
| 2025-09-30 | $33.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $84.33M derived: sum of 2 quarters · filed 2026-08-04 | $134.98M 10-Q · filed 2025-11-05 | $179.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $51.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $101.79M 10-Q · filed 2026-08-04 | $146.59M derived: sum of 3 quarters · filed 2026-08-04 | $209.85M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $50.65M 10-Q · filed 2026-05-05 | $95.45M derived: sum of 2 quarters · filed 2026-05-05 | $158.71M derived: sum of 3 quarters · filed 2026-05-05 | $241.43M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $44.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $108.06M derived: sum of 2 quarters · filed 2026-02-26 | $190.78M derived: sum of 3 quarters · filed 2026-02-26 | $244.26M 10-K · filed 2026-02-26 |
| 2024-09-30 | $63.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $145.98M derived: sum of 2 quarters · filed 2025-11-05 | $199.46M 10-Q · filed 2025-11-05 | $321.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $82.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $136.20M 10-Q · filed 2025-08-05 | $258.19M derived: sum of 3 quarters · filed 2026-02-26 | $377.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $53.48M 10-Q · filed 2025-05-01 | $175.47M derived: sum of 2 quarters · filed 2026-02-26 | $294.56M derived: sum of 3 quarters · filed 2026-02-26 | $393.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $122.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $241.08M derived: sum of 2 quarters · filed 2026-02-26 | $340.46M derived: sum of 3 quarters · filed 2026-02-26 | $429.56M 10-K · filed 2026-02-26 |
| 2023-09-30 | $119.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $218.47M derived: sum of 2 quarters · filed 2024-11-07 | $307.56M 10-Q · filed 2024-11-07 | $472.60M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $99.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $188.48M 10-Q · filed 2024-08-01 | $353.51M derived: sum of 3 quarters · filed 2025-03-03 | $382.07M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $89.10M 10-Q · filed 2024-05-07 | $254.13M derived: sum of 2 quarters · filed 2025-03-03 | $282.68M derived: sum of 3 quarters · filed 2025-03-03 | $307.64M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $165.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $193.59M derived: sum of 2 quarters · filed 2025-03-03 | $218.54M derived: sum of 3 quarters · filed 2025-03-03 | $278.78M 10-K · filed 2025-03-03 |
| 2022-09-30 | $28.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $53.51M derived: sum of 2 quarters · filed 2023-11-09 | $113.74M 10-Q · filed 2023-11-09 | $192.29M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $24.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $85.19M 10-Q · filed 2023-08-02 | $163.73M derived: sum of 3 quarters · filed 2024-02-29 | $305.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $60.23M 10-Q · filed 2023-05-03 | $138.78M derived: sum of 2 quarters · filed 2024-02-29 | $280.43M derived: sum of 3 quarters · filed 2024-02-29 | $361.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $78.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $220.19M derived: sum of 2 quarters · filed 2024-02-29 | $301.20M derived: sum of 3 quarters · filed 2024-02-29 | $316.54M 10-K · filed 2024-02-29 |
| 2021-09-30 | $141.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $222.66M derived: sum of 2 quarters · filed 2022-11-03 | $238.00M 10-Q · filed 2022-11-03 | $633.18M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $81.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $96.35M 10-Q · filed 2022-08-03 | $491.53M derived: sum of 3 quarters · filed 2023-02-14 | $683.57M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $15.34M 10-Q · filed 2022-05-04 | $410.52M derived: sum of 2 quarters · filed 2023-02-14 | $602.56M derived: sum of 3 quarters · filed 2023-02-14 | $602.56M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $395.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $587.22M derived: sum of 2 quarters · filed 2023-02-14 | $587.22M derived: sum of 3 quarters · filed 2023-02-14 | $694.97M 10-K · filed 2023-02-14 |
| 2020-09-30 | $192.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $192.04M derived: sum of 2 quarters · filed 2021-11-03 | $299.79M 10-Q · filed 2021-11-03 | $411.91M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $107.75M 10-Q · filed 2021-08-04 | $219.87M derived: sum of 3 quarters · filed 2022-02-15 | $633.29M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $107.75M 10-Q · filed 2021-05-05 | $219.87M derived: sum of 2 quarters · filed 2022-02-15 | $633.29M derived: sum of 3 quarters · filed 2022-02-15 | $721.10M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $112.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $525.55M derived: sum of 2 quarters · filed 2022-02-15 | $613.36M derived: sum of 3 quarters · filed 2022-02-15 | $884.22M 10-K · filed 2022-02-15 |
| 2019-09-30 | $413.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $501.23M derived: sum of 2 quarters · filed 2020-11-10 | $772.09M 10-Q · filed 2020-11-10 | $781.47M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $87.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $358.67M 10-Q · filed 2020-08-10 | $368.05M derived: sum of 3 quarters · filed 2021-02-24 | $394.23M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $270.86M 10-Q · filed 2020-05-12 | $280.24M derived: sum of 2 quarters · filed 2021-02-24 | $306.42M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $35.56M derived: sum of 2 quarters · filed 2021-02-24 | $146.50M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $26.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $137.12M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $110.95M 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | $125.18M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |